Repligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference
May 31 2017 - 7:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that
management will present at Jefferies’ 2017 Global Annual Healthcare
Conference, to be held June 6-9, 2017 in New York. The
Repligen presentation is scheduled for Wednesday, June 7 at 10:30
a.m.
A live webcast of the presentation will be accessible through
the Investor Events section of the Company’s website, and will be
available for replay for a limited period of time following the
conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a
bioprocessing company focused on the development, manufacture and
commercialization of highly innovative products used to improve the
biological drug manufacturing process. Our portfolio includes
Protein products (Protein A affinity ligands, cell culture growth
factors), Chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and Filtration products (XCell™
ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing
products are sold to major life sciences companies,
biopharmaceutical development companies and contract manufacturing
organizations worldwide. We are the leading manufacturer of Protein
A ligands, a critical component of Protein A resins that are the
industry standard for downstream separation and purification of
monoclonal antibody-based therapeutics. Our growth factors are a
key component of cell culture media used in upstream processes to
accelerate cell growth and productivity in a bioreactor. Our
innovative line of OPUS® chromatography columns, used in downstream
processes for bench-scale through clinical-scale purification
needs, are delivered pre-packed with our customers’ choice of resin
and bed height. Our XCell™ ATF Systems, available in stainless
steel and single-use configurations, continuously eliminate waste
from a bioreactor to concentrate cells in upstream processes.
TangenX Sius™ TFF single-use cassettes and hardware are used for
biologic drug concentration in downstream formulation processes.
Repligen’s corporate headquarters are in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA, Shrewsbury,
MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Contact:
Sondra Newman
snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024